









Markets
/
Stocks
/
nasdaq-glue
/

Monte Rosa Therapeutics Inc

GLUE

19.550USD

+0.650+3.44%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

1.21BMarket Cap

61.50P/E TTM



Monte Rosa Therapeutics Inc

19.550

+0.650+3.44%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Monte Rosa Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Monte Rosa Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 45 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 29.29.In the medium term, the stock price is expected to trend up.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Monte Rosa Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

45 / 392

Overall Ranking

151 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Monte Rosa Therapeutics Inc Highlights

StrengthsRisks

Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.

Growing

The company is in a growing phase, with the latest annual income totaling USD 75.62M.

Overvalued

The company’s latest PE is 61.50, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 70.21M shares, increasing 1.50% quarter-over-quarter.

Held by Chuck Royce

Star Investor Chuck Royce holds 11.02K shares of this stock.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

29.286

Target Price

+49.95%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Monte Rosa Therapeutics Inc is 7.65, ranking 88 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 12.77M, representing a year-over-year increase of 38.54%, while its net profit experienced a year-over-year increase of 13.50%.

Score

Industry at a Glance

Previous score

7.65

Change



Financials

9.09

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

3.72

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.09

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.32

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Monte Rosa Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Monte Rosa Therapeutics Inc is 7.26, ranking 143 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is 61.50, which is 29.46% below the recent high of 79.61 and 111.85% above the recent low of -7.29.

Score

Industry at a Glance

Previous score

7.26

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 45/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Monte Rosa Therapeutics Inc is 8.67, ranking 70 out of 392 in the Biotechnology & Medical Research industry. The average price target is 18.00, with a high of 20.00 and a low of 13.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

29.286

Target Price

+49.95%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Monte Rosa Therapeutics Inc

GLUE

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Monte Rosa Therapeutics Inc is 6.76, ranking 177 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 23.65 and the support level at 17.15, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.59

Change

0.17

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-1.332

Neutral

RSI(14)

44.938

Neutral

STOCH(KDJ)(9,3,3)

11.327

Oversold

ATR(14)

1.448

Low Volatility

CCI(14)

-101.112

Sell

Williams %R

89.277

Oversold

TRIX(12,20)

0.286

Sell

StochRSI(14)

39.714

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

19.958

Sell

MA10

20.829

Sell

MA20

22.333

Sell

MA50

19.108

Buy

MA100

14.777

Buy

MA200

9.774

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Monte Rosa Therapeutics Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 97.11%, representing a quarter-over-quarter decrease of 4.80%. The largest institutional shareholder is PRFDX, holding a total of 4.54M shares, representing 6.23% of shares outstanding, with 41.52% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

New Enterprise Associates (NEA)

7.69M

Dimension Management, L.P.

4.76M

BVF Partners L.P.

5.66M

Baker Bros. Advisors LP

4.92M

T. Rowe Price Associates, Inc.

Star Investors

4.54M

-27.09%

TCG Crossover Management, LLC

4.43M

Suvretta Capital Management, LLC

3.36M

BlackRock Institutional Trust Company, N.A.

3.30M

-1.64%

Versant Ventures

4.91M

-13.18%

The Vanguard Group, Inc.

Star Investors

2.99M

-4.83%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Monte Rosa Therapeutics Inc is 3.20, ranking 165 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.63. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Monte Rosa Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.